Oculis SA
Next Generation of Topical Ophthalmic Treatments
Oculis S.A. is a biopharmaceutical company focused on developing transformative topical ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients.
Oculis' novel topical (eye drop) treatments are non-invasive and represent an unprecedented technical advance for patients with retinal and front-of-the-eye diseases.
The Company's leading clinical candidates are:
- OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone based on Oculis' proprietary Solubilizing Nanoparticle (SNP) technology.
- OCS-02 is a novel topical anti-TNF alpha antibody.
In addition, Oculis' formulation discovery focus and capabilities are enabling the development of topical drugs targeting sight-threatening diseases.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
05.08.2025
Oculis secures CHF 100 million loan facility to accelerate eye care innovation (venturelab.swiss)
04.08.2025
Oculis upsized loan facility to access up to CHF 100 million (startupticker.ch)
14.02.2025
Oculis raises USD 100 Million in oversubscribed share offering (venturelab.swiss)
14.02.2025
Oculis raises USD 100 million (startupticker.ch)
09.01.2025
Positive developments at Swiss biotech companies (startupticker.ch)
No milestones
No Jobs
Videos
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Oculis SA
Next Generation of Topical Ophthalmic Treatments
Website:
www.oculis.com
Headquarter:
Lausanne
Foundation Date:
December 2017
Technology:
- Biotech
Sectors:
- Biotech
Support received
